INOVIO (INO) reported a second-quarter 2026 net loss of $6.0 million, or $0.07 per basic and diluted share, compared with a net loss of $23.5 million, or $0.61 per basic and diluted share, a year earlier. Total operating expenses decreased to $18.6 million from $23.1 million.
The company said the FDA review of its Biologics License Application for INO-3107 as a treatment for recurrent respiratory papillomatosis is advancing, with a PDUFA target action date of October 30, 2026. INOVIO said cash, cash equivalents and short-term investments are expected to fund operations into late first quarter 2027, including July 2026 offering proceeds of about $18.3 million.
- R&D expenses were $10.8 million for the quarter, down from $14.5 million in the same period of 2025.
- G&A expenses were $7.8 million, compared with $8.6 million a year earlier.
- Cash, cash equivalents and short-term investments totaled $36.7 million at June 30, 2026, excluding July offering proceeds.
- ApolloBio reported positive topline Phase 3 results for VGX-3100 in cervical dysplasia patients in China.
- INOVIO presented preclinical data from its DMAb and DPROT programs at scientific conferences during the quarter.
$INO Hedge Fund Activity
We have seen 38 institutional investors add shares of $INO stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,623,613 shares (-76.5%) from their portfolio in Q1 2026, for an estimated $4,565,086
- EVERSEPT PARTNERS, LP added 1,035,360 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,801,526
- FMR LLC removed 507,050 shares (-5.1%) from their portfolio in Q1 2026, for an estimated $882,267
- CITADEL ADVISORS LLC added 286,352 shares (+inf%) to their portfolio in Q1 2026, for an estimated $498,252
- QUADRATURE CAPITAL LTD added 258,928 shares (+inf%) to their portfolio in Q2 2026, for an estimated $284,820
- OMERS ADMINISTRATION CORP removed 223,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $388,020
- GSA CAPITAL PARTNERS LLP removed 194,817 shares (-42.4%) from their portfolio in Q2 2026, for an estimated $214,298
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
